{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T07:29:01Z","timestamp":1773041341000,"version":"3.50.1"},"reference-count":100,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Horm Metab Res"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pituitary adenomas are benign tumors of the anterior portion of the pituitary\n                    gland (adenohypophysis), representing the 25% of all the tumor\n                    alterations. Pituitary adenomas are classified by the type of hormone secreted,\n                    cellularity, size, and structural alterations by the hormonal segregation. The\n                    diagnosis consists on the histopathological identification of cell types and the\n                    image-guided by magnetic resonance or tomography; the treatment can be both\n                    pharmacological and surgical. Metabolic Syndrome is the set of clinical\n                    conditions that increase the risk of cardiovascular diseases with an estimated\n                    prevalence of 25% worldwide. The alterations of metabolic syndrome are\n                    obesity, hypertension, dyslipidemia, insulin resistance, and diabetes mellitus\n                    type II. Pituitary adenomas and metabolic syndrome have an important\n                    relationship, hormone-secreting by pituitary adenomas affects a myriad of\n                    signaling pathways, which allows a favorable environment for the appearance of\n                    the metabolic syndrome. Moreover, patients with pituitary adenomas are shown to\n                    have an improvement in metabolic parameters after the medical\/surgical\n                    treatment. The objective of this review is to explore the possible mechanisms\n                    through which PAs contributes to MetSx.<\/jats:p>","DOI":"10.1055\/a-2209-0538","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T23:52:31Z","timestamp":1702338751000},"page":"118-127","source":"Crossref","is-referenced-by-count":3,"title":["Metabolic Syndrome Components in Patients with Pituitary\n                    Adenoma"],"prefix":"10.1055","volume":"56","author":[{"given":"Jorge A.","family":"Gonzalez-Almazan","sequence":"additional","affiliation":[{"name":"Research Division, General Hospital of Mexico, Ciudad de Mexico,\n                    Mexico"},{"name":"Functional & Stereotactic Neurosurgery Unit, General Hospital\n                    of Mexico, Ciudad de Mexico, Mexico"},{"name":"Facultad de Estudios Superiores Iztacala, Universidad Nacional Autonoma\n                    de Mexico Facultad de Estudios Superiores Iztacala, Tlalnepantla,\n                    Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Paula","family":"Cortes-Contreras","sequence":"additional","affiliation":[{"name":"Research Division, General Hospital of Mexico, Ciudad de Mexico,\n                    Mexico"},{"name":"Functional & Stereotactic Neurosurgery Unit, General Hospital\n                    of Mexico, Ciudad de Mexico, Mexico"},{"name":"Faculty of Medicine, National Autonomous University of Mexico, Ciudad\n                    de Mexico, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina","family":"Flores-Rabasa","sequence":"additional","affiliation":[{"name":"Research Division, General Hospital of Mexico, Ciudad de Mexico,\n                    Mexico"},{"name":"Faculty of Health Sciences, Anahuac University Mexico \u2013\n                    Southern Campus, Ciudad de Mexico, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia A.","family":"Mendez-Garcia","sequence":"additional","affiliation":[{"name":"Research Division, General Hospital of Mexico, Ciudad de Mexico,\n                    Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galileo","family":"Escobedo","sequence":"additional","affiliation":[{"name":"Research Division, General Hospital of Mexico, Ciudad de Mexico,\n                    Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 L.","family":"Navarro Olvera","sequence":"additional","affiliation":[{"name":"Functional & Stereotactic Neurosurgery Unit, General Hospital\n                    of Mexico, Ciudad de Mexico, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 D.","family":"Carrillo-Ruiz","sequence":"additional","affiliation":[{"name":"Research Division, General Hospital of Mexico, Ciudad de Mexico,\n                    Mexico"},{"name":"Functional & Stereotactic Neurosurgery Unit, General Hospital\n                    of Mexico, Ciudad de Mexico, Mexico"},{"name":"Coordination of Neuroscience, Faculty of Psychology, University Anahuac\n                    Mexico, Huixquilucan, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,12,11]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1172\/JCI114705","article-title":"Clinically nonfunctioning pituitary tumors are monoclonal in origin","volume":"86","author":"J M Alexander","year":"1990","journal-title":"J Clin Invest"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1210\/jcem-71-6-1427","article-title":"Clonal origin of pituitary adenomas","volume":"71","author":"V Herman","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.4158\/EP-2018-0034","article-title":"Update on the clinicopathology of pituitary adenomas","volume":"24","author":"C T Lim","year":"2018","journal-title":"Endocr Pract"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1242\/dmm.001180","article-title":"A comprehensive definition for metabolic syndrome","volume":"2","author":"P L Huang","year":"2009","journal-title":"DMM Dis Model Mech"},{"key":"ref5","first-page":"2852710","article-title":"Cardiovascular risk and metabolic syndrome characteristics in patients with\n                    nonfunctional pituitary macroadenoma","author":"G Vargas-Ortega","year":"2018","journal-title":"Int J Endocrinol"},{"key":"ref6","first-page":"357","article-title":"Metabolic abnormalities in pituitary adenoma patients: a novel therapeutic\n                    target and prognostic factor","volume":"8","author":"X Zheng","year":"2015","journal-title":"Diabetes, Metab Syndr Obes Targets Ther"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ecl.2020.04.002","article-title":"The epidemiology of pituitary adenomas","volume":"49","author":"A F Daly","year":"2020","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1080\/0284186X.2017.1330554","article-title":"Overweight, obesity and height as risk factors for meningioma, glioma, pituitary\n                    adenoma and nerve sheath tumor: a large population-based prospective cohort\n                    study","volume":"56","author":"MK H Wiedmann","year":"2017","journal-title":"Acta Oncol (Madr)"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","article-title":"Overview of the 2022 WHO classification of pituitary tumors","volume":"33","author":"S L Asa","year":"2022","journal-title":"Endocr Pathol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.3390\/jcm11061581","article-title":"Neurological presentation of giant pituitary tumour apoplexy: case report and\n                    literature review of a rare but life-threatening condition","volume":"11","author":"V Puglisi","year":"2022","journal-title":"J Clin Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","article-title":"Guidelines of the Pituitary Society for the diagnosis and management of\n                    prolactinomas","volume":"65","author":"F F Casanueva","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1530\/EJE-07-0248","article-title":"Operative treatment of prolactinomas: Indications and results in a current\n                    consecutive series of 212 patients","volume":"158","author":"J Kreutzer","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s11102-010-0283-y","article-title":"Pituitary surgery for small prolactinomas as an alternative to treatment with\n                    dopamine agonists","volume":"14","author":"M Babey","year":"2011","journal-title":"Pituitary"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1210\/jc.2011-0251","article-title":"Radiation therapy in the management of pituitary adenomas","volume":"96","author":"J S Loeffler","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3389\/fsurg.2021.806855","article-title":"Endoscopic vs. microscopic transsphenoidal surgery for the treatment of\n                    pituitary adenoma: a meta-analysis","volume":"8","author":"J Chen","year":"2022","journal-title":"Front Surg"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.3390\/jcm12041654","article-title":"Delving into acromegaly","volume":"12","author":"S St\u00f6rmann","year":"2023","journal-title":"J Clin Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1210\/jc.2005-2347","article-title":"Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine\n                    years) prospective study of its efficacy in the control of disease activity and\n                    tumor shrinkage","volume":"91","author":"R Cozzi","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1210\/jc.2015-1818","article-title":"Treatment of cushing\u2019s syndrome: an endocrine society clinical practice\n                    guideline","volume":"100","author":"L K Nieman","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1210\/jc.2011-3350","article-title":"Mifepristone, a glucocorticoid receptor antagonist, produces clinical and\n                    metabolic benefits in patients with Cushing\u2019s syndrome","volume":"97","author":"M Fleseriu","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2265.2007.03082.x","article-title":"Bilateral laparoscopic adrenalectomy for corticotrophin-dependent\n                    Cushing\u2019s syndrome: a review of the Mayo Clinic experience","volume":"68","author":"J T Chow","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000351007","article-title":"2013 European Thyroid Association guidelines for the diagnosis and treatment of\n                    thyrotropin-secreting pituitary tumors","volume":"2","author":"P Beck-Peccoz","year":"2013","journal-title":"Eur Thyroid J"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1530\/eje.0.1480433","article-title":"The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and\n                    management in 43 patients","volume":"148","author":"H V Socin","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1210\/jc.2013-4376","article-title":"Thyrotropin-secreting pituitary adenomas: outcome of pituitary surgery and\n                    irradiation","volume":"99","author":"E Malchiodi","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"ref24","first-page":"237","article-title":"Surgical management of pituitary tumors","volume":"80","author":"A Bartal","year":"1971","journal-title":"Harefuah"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1530\/EJE-10-0255","article-title":"Factors predicting relapse of nonfunctioning pituitary macroadenomas after\n                    neurosurgery: a study of 142 patients","volume":"163","author":"S Brochier","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.2337\/dc12-0336","article-title":"Metabolic syndrome and risk of cancer: a systematic review and\n                    meta-analysis","volume":"35","author":"K Esposito","year":"2012","journal-title":"Diabetes Care"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/1753944717711379","article-title":"Metabolic syndrome: pathophysiology, management, and modulation by natural\n                    compounds","volume":"11","author":"Y Rochlani","year":"2017","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1741-7015-9-48","article-title":"Metabolic syndrome: definitions and controversies","volume":"9","author":"E Kassi","year":"2011","journal-title":"BMC Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"786","DOI":"10.3390\/ijms23020786","article-title":"Metabolic syndrome: updates on pathophysiology and management in 2021","volume":"23","author":"G Fahed","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000443743","article-title":"Association between metabolic syndrome and cancer","volume":"68","author":"M Uzunlulu","year":"2016","journal-title":"Ann Nutr Metab"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.3390\/ijms20051146","article-title":"Obesity, DNA damage, and development of obesity-related diseases","volume":"20","author":"M W\u0142odarczyk","year":"2019","journal-title":"Int J Mol Sci"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.tem.2016.08.004","article-title":"Emerging concepts linking obesity with the hallmarks of cancer","volume":"28","author":"C L Donohoe","year":"2017","journal-title":"Trends Endocrinol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/oby.2010.150","article-title":"BMI and metabolic profile in patients with prolactinoma before and after\n                    treatment with dopamine agonists","volume":"19","author":"C M Dos Santos Silva","year":"2011","journal-title":"Obesity"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11102-008-0097-3","article-title":"The effects of hyperprolactinemia on bone and fat","volume":"12","author":"A Shibli-Rahhal","year":"2009","journal-title":"Pituitary"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1210\/jc.2009-2570","article-title":"Cardiovascular risk factors in patients with uncontrolled and long-term\n                    acromegaly: comparison with matched data from the general population and the\n                    effect of disease control","volume":"95","author":"C Berg","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1365-2265.2008.03323.x","article-title":"Alterations in biomarkers of cardiovascular disease (CVD) in active\n                    acromegaly","volume":"70","author":"L Boero","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s11102-011-0365-5","article-title":"Clinical and metabolic effects of first-line treatment with somatostatin\n                    analogues or surgery in acromegaly: a retrospective and comparative study","volume":"15","author":"C Giordano","year":"2012","journal-title":"Pituitary"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1530\/eje.0.1470077","article-title":"Dopaminergic tone and obesity: an insight from prolactinomas treated with\n                    bromocriptine","volume":"147","author":"M Doknic","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.1365-2265.1998.00403.x","article-title":"Increased body weight associated with prolactin secreting pituitary adenomas:\n                    weight loss with normalization of prolactin levels","volume":"48","author":"Y Greenman","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2176\/nmc.oa.2017-0215","article-title":"Postoperative changes in metabolic parameters of patients with surgically\n                    controlled acromegaly: assessment of new stringent cure criteria","volume":"58","author":"M Yonenaga","year":"2018","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s12020-018-1797-8","article-title":"Changes in metabolic parameters and cardiovascular risk factors after\n                    therapeutic control of acromegaly vary with the treatment modality. Data from\n                    the Bic\u00eatre cohort, and review of the literature","volume":"63","author":"C Briet","year":"2019","journal-title":"Endocrine"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1055\/a-1020-3992","article-title":"Markers of metabolic syndrome in patients with pituitary adenoma: a case series\n                    of 303 patients","volume":"51","author":"S\u00c7 Altunta\u015b","year":"2019","journal-title":"Horm Metab Res"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.tem.2020.01.004","article-title":"Time for a new perspective on prolactin in metabolism","volume":"31","author":"Y Macotela","year":"2020","journal-title":"Trends Endocrinol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11154-019-09503-1","article-title":"Prolactin and human weight disturbances: A puzzling and neglected\n                    association","volume":"20","author":"L G Sobrinho","year":"2019","journal-title":"Rev Endocr Metab Disord"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.aace.2021.01.004","article-title":"Morbid obesity due to prolactinoma and significant weight loss after dopamine\n                    agonist treatment","volume":"7","author":"M Ali","year":"2021","journal-title":"AACE Clin Case Rep"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/17446651.2018.1434412","article-title":"The effects of hyperprolactinemia and its control on metabolic diseases","volume":"13","author":"R S Auriemma","year":"2018","journal-title":"Expert Rev Endocrinol Metab"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13098-015-0094-4","article-title":"Metabolic abnormalities in patients with prolactinoma: response to treatment\n                    with cabergoline","volume":"7","author":"N A Pala","year":"2015","journal-title":"Diabetol Metab Syndr"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1007\/s12020-013-9931-0","article-title":"Evaluation of body weight, insulin resistance, leptin and adiponectin levels in\n                    premenopausal women with hyperprolactinemia","volume":"44","author":"A Atmaca","year":"2013","journal-title":"Endocrine"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"101319","DOI":"10.1016\/j.ghir.2020.101319","article-title":"Mechanisms of putative IGF-I receptor resistance in active acromegaly","volume":"52","author":"J A Janssen","year":"2020","journal-title":"Growth Horm IGF Res"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/cen.14461","article-title":"In patients with controlled acromegaly, indices of glucose homeostasis correlate\n                    with IGF-1 levels rather than with type of treatment","volume":"95","author":"A Decock","year":"2021","journal-title":"Clin Endocrinol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1210\/jc.2007-2780","article-title":"Lower visceral and subcutaneous but higher intermuscular adipose tissue depots\n                    in patients with growth hormone and insulin-like growth factor I excess due to\n                    acromegaly","volume":"93","author":"P U Freda","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/jamasurg.2020.3280","article-title":"Evaluation and treatment of patients with hypercortisolism: a review","volume":"155","author":"B S Miller","year":"2020","journal-title":"JAMA Surg"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000486002","article-title":"Metabolic syndrome in cushing\u2019s syndrome patients","volume":"49","author":"F Ferra\u00f9","year":"2018","journal-title":"Front Horm Res"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1210\/jc.2009-0370","article-title":"The pathogenetic role of cortisol in the metabolic syndrome: A hypothesis","volume":"94","author":"P Anagnostis","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"580264","DOI":"10.3389\/fendo.2020.580264","article-title":"Progress in the pathogenesis, diagnosis, and treatment of TSH-secreting\n                    pituitary neuroendocrine tumor","volume":"11","author":"P Luo","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2147\/IJGM.S206983","article-title":"Relationship between thyroid dysfunction and body weight: a not so evident\n                    paradigm","volume":"12","author":"M R\u00edos-Prego","year":"2019","journal-title":"Int J Gen Med"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s40618-019-01066-x","article-title":"A 2019 update on TSH-secreting pituitary adenomas","volume":"42","author":"P Beck-Peccoz","year":"2019","journal-title":"J Endocrinol Invest"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cob.12328","article-title":"Weight gain following treatment of hyperthyroidism \u2013 a forgotten\n                    tale","volume":"9","author":"A Kyriacou","year":"2019","journal-title":"Clin Obes"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11102-018-0869-3","article-title":"Epidemiology, clinical presentation and diagnosis of non-functioning pituitary\n                    adenomas","volume":"21","author":"G Ntali","year":"2018","journal-title":"Pituitary"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.endinu.2017.05.009","article-title":"Clinically non-functioning pituitary adenomas: pathogenic, diagnostic and\n                    therapeutic aspects","volume":"64","author":"M Mercado","year":"2017","journal-title":"Endocrinol Diabetes Nutr"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1179551420932921","DOI":"10.1177\/1179551420932921","article-title":"Contemporary management of clinically non-functioning pituitary adenomas: a\n                    clinical review","volume":"13","author":"M H AlMalki","year":"2020","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1097\/HJH.0b013e328339f254","article-title":"Plasma prolactin level and risk of incident hypertension in postmenopausal\n                    women","volume":"28","author":"L Zhang","year":"2010","journal-title":"J Hypertens"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3109\/0886022X.2012.672313","article-title":"Hyperprolactinemia as a rare cause of hypertension in chronic renal failure","volume":"34","author":"K Gulleroglu","year":"2012","journal-title":"Ren Fail"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/9524839","article-title":"Relationship between prolactin, chronic kidney disease, and cardiovascular\n                    risk","volume":"9524839","author":"M Dourado","year":"2020","journal-title":"Int J Endocrinol"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"64","DOI":"10.14797\/mdcj-13-2-64","article-title":"Cardiovascular disease in acromegaly","volume":"13","author":"M D Sharma","year":"2017","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11102-017-0797-7","article-title":"Complications of acromegaly: cardiovascular, respiratory and metabolic\n                    comorbidities","volume":"20","author":"R Pivonello","year":"2017","journal-title":"Pituitary"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.ecl.2019.08.008","article-title":"Hypertension and acromegaly","volume":"48","author":"S Puglisi","year":"2021","journal-title":"Endocrinol Metab Clin Nam"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/HJH.0000000000000415","article-title":"The hypertension of Cushing\u2019s syndrome: controversies in the\n                    pathophysiology and focus on cardiovascular complications","volume":"33","author":"A M Isidori","year":"2015","journal-title":"J Hypertens"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2213-8587(16)00086-3","article-title":"Complications of Cushing\u2019s syndrome: state of the art","volume":"4","author":"R Pivonello","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3389\/fendo.2019.00321","article-title":"The pathophysiology and treatment of hypertension in patients with\n                    Cushing\u2019s syndrome","volume":"10","author":"M Barbot","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.ecl.2019.08.005","article-title":"Hypertension and cardiovascular mortality in patients with Cushing syndrome","volume":"48","author":"L K Nieman","year":"2019","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3389\/fendo.2019.00482","article-title":"Hypertension in thyroid disorders","volume":"10","author":"E Berta","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref73","first-page":"167","article-title":"Hyperthyroidism and the heart","volume":"20","author":"J Jiskra","year":"2018","journal-title":"Kardiol Rev"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"68","DOI":"10.14740\/cr1034","article-title":"Thyroid and cardiovascular disease: a focused review on the impact of\n                    hyperthyroidism in heart failure","volume":"11","author":"R Khan","year":"2020","journal-title":"Cardiol Res"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.amjms.2020.08.012","article-title":"Hypertension and hyperthyroidism: association and pathogenesis","volume":"361","author":"A M Rivas","year":"2021","journal-title":"Am J Med Sci"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1472-6823-13-12","article-title":"Serum prolactin concentrations as risk factor of metabolic syndrome or type 2\n                    diabetes?","volume":"13","author":"L Balbach","year":"2013","journal-title":"BMC Endocr Disord"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3389\/fendo.2019.00327","article-title":"Glucose abnormalities associated to prolactin secreting pituitary adenomas","volume":"10","author":"R S Auriemma","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1055\/a-1258-8625","article-title":"The effect of pituitary gland disorders on glucose metabolism: from\n                    pathophysiology to management","volume":"53","author":"G I Sydney","year":"2021","journal-title":"Horm Metab Res"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"e0175204","DOI":"10.1371\/journal.pone.0175204","article-title":"Association between serum prolactin levels and insulin resistance in\n                    non-diabetic men","volume":"12","author":"M Daimon","year":"2017","journal-title":"PLoS One"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.tem.2016.04.014","article-title":"Current and emerging aspects of diabetes mellitus in acromegaly","volume":"27","author":"S Frara","year":"2016","journal-title":"Trends Endocrinol Metab"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11892-017-0838-7","article-title":"Diabetes in patients with acromegaly","volume":"17","author":"A M Hannon","year":"2017","journal-title":"Curr Diab Rep"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3389\/fendo.2018.00358","article-title":"Diabetes secondary to acromegaly: Physiopathology, clinical features and effects\n                    of treatment","volume":"9","author":"F Ferra\u00f9","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref83","first-page":"139","article-title":"Glucose metabolism in Cushing syndrome","volume":"176","author":"A V Ani Sharma","year":"2017","journal-title":"Physiol Behav"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11892-017-0860-9","article-title":"Diabetes in Cushing disease","volume":"17","author":"G Mazziotti","year":"2017","journal-title":"Curr Diab Rep"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2213-8587(16)00086-3","article-title":"Complications of Cushing\u2019s syndrome: state of the art","volume":"4","author":"R Pivonello","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3389\/fendo.2018.00284","article-title":"Diabetes mellitus secondary to Cushing\u2019s disease","volume":"9","author":"M Barbot","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1210\/er.2016-1105","article-title":"Glucose metabolism abnormalities in cushing syndrome: from molecular basis to\n                    clinical management","volume":"38","author":"C Scaroni","year":"2017","journal-title":"Endocr Rev"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/10715762.2019.1590567","article-title":"Insulin resistance and diabetes in hyperthyroidism: a possible role for oxygen\n                    and nitrogen reactive species","volume":"53","author":"P Venditti","year":"2019","journal-title":"Free Radic Res"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s13300-019-00700-4","article-title":"Thyroid dysfunction and type 2 diabetes mellitus: screening strategies and\n                    implications for management","volume":"10","author":"S Kalra","year":"2019","journal-title":"Diabetes Ther"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11011-016-9882-2","article-title":"Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients\n                    with prolactinomas","author":"V Schwetz","year":"2017","journal-title":"Metab Brain Dis"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"769744","DOI":"10.3389\/fendo.2021.769744","article-title":"Effects of pituitary surgery and high-dose cabergoline therapy on metabolic\n                    profile in patients with prolactinoma resistant to conventional cabergoline\n                    treatment","volume":"12","author":"R Pirchio","year":"2021","journal-title":"Front Endocrinol"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/oby.2010.150","article-title":"BMI and metabolic profile in patients with prolactinoma before and after\n                    treatment with dopamine agonists","volume":"19","author":"M Cintia","year":"2011","journal-title":"Obesity"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"630","DOI":"10.20945\/2359-3997000000193","article-title":"Determinants of morbidities and mortality in acromegaly","volume":"63","author":"L Kasuki","year":"2019","journal-title":"Arch Endocrinol Metab"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s11154-020-09560-x","article-title":"Acromegaly, inflammation and cardiovascular disease: a review","volume":"21","author":"TL C Wolters","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"101380","DOI":"10.1016\/j.beem.2020.101380","article-title":"Cushing\u2019s syndrome: overview of clinical presentation, diagnostic tools\n                    and complications","volume":"34","author":"M Barbot","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"M133","DOI":"10.1530\/EJE-15-0354","article-title":"Metabolic comorbidities in Cushing\u2019s syndrome","volume":"173","author":"F Ferra\u00f9","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"ref97","doi-asserted-by":"crossref","first-page":"76","DOI":"10.32553\/ijmbs.v3i6.301","article-title":"Effects of thyroid dysfunction on lipid profile","volume":"3","author":"D V Kumar","year":"2019","journal-title":"Int J Med Biomed Stud"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"2042018820917869","DOI":"10.1177\/2042018820917869","article-title":"The role of thyroid hormone in metabolism and metabolic syndrome","volume":"11","author":"PDFD S Teixeira","year":"2020","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref99","first-page":"1043","article-title":"Update on lipid metabolism and thyroid disorders. J Endocrinol Diabetes","volume":"2","author":"T Jin","year":"2014","journal-title":"Obes Rev"},{"key":"ref100","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.mcna.2012.01.012","article-title":"The effect of thyroid disorders on lipid levels and metabolism","volume":"96","author":"L H Duntas","year":"2012","journal-title":"Med Clin North Am"}],"container-title":["Hormone and Metabolic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2209-0538.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T11:21:30Z","timestamp":1730805690000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2209-0538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,11]]},"references-count":100,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2024,1,29]]},"published-print":{"date-parts":[[2024,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2209-0538","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0018-5043","1439-4286"],"issn-type":[{"value":"0018-5043","type":"print"},{"value":"1439-4286","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,11]]}}}